

Calendar Year 2011 Annual Review of Fibric Acid Derivatives

Oklahoma HealthCare Authority
April 2012

Prior Authorization of Fibric Acid Derivatives

The approval criteria for a tier-2 medication is as follows:

- Laboratory documented failure after 6 months trial with a tier one medication.
- Documented adverse effect, drug interaction, or contraindication to tier-1 products.
- Prior stabilization on the tier-2 medication documented within the last 100 days.

Fibric Acid Derivatives	
Tier One	Tier Two
Fenofibrate (Lofibra [®] Caps)	Fenofibrate (Antara [®] Caps)
Fenofibrate (Trilipix[®] Tabs)	Fenofibrate (Triglide [®] Tabs) 50mg, 160mg
Fenofibrate (Tricor[®] Tabs)	Fenofibrate (Lipofen [®] Caps)
Gemfibrozil (Lopid [®] Tabs)	Fenofibrate (Fenoglide [®] Tabs)
Clofibrate (Atromid-S [®] Caps)	


Tiers based on Supplemental Rebate Participation

Utilization of Fibric Acid Derivatives


Utilization Trends

Calendar Year	Members	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2010	2,479	10,134	\$887,842.16	\$87.61	\$2.34	515,493	380,225
2011	2,866	11,854	\$1,112,156.09	\$93.82	\$2.51	596,025	443,294
% Change	15.60%	17.00%	25.30%	7.10%	7.30%	15.60%	16.60%
Change	387	1,720	\$224,313.93	\$6.21	\$0.17	80,532	63,069

Demographics for CY 2011




Prescriber Specialty by Number of Claims for CY 2011



Prior Authorization of Fibric Acid Derivatives

There were a total of 58 petitions submitted for this PBPA category during Calendar Year 2011. Computer edits are in place to look for Tier 1 medications, and if detected, the medication will not require a petition. The following chart shows the status of the submitted petitions:



Market News and Update

November 2011 - The U.S. Food and Drug Administration (FDA) informed the public that the cholesterol-lowering medicine Trilipix® (fenofibric acid) may not lower a patient's risk of having a heart attack or stroke. This is based on data from the **Action to Control Cardiovascular Risk in Diabetes (ACCORD Lipid)** trial, which evaluated the efficacy and safety of fenofibrate plus simvastatin combination therapy versus simvastatin alone in patients with type 2 diabetes mellitus.

Anticipated Patent Expirations:

1. Trilipix® – 2025
2. Tricor® – 2018
3. Antara® – 2020
4. Fenoglide® – 2024
5. Triglide® – 2021
6. Lipofen® – 2015

Recommendation

The College of Pharmacy recommends continued monitoring of this category.

Utilization Details of Fibric Acid Derivatives: CY 2011

Chemical Name	Brand Name	Claims	Members	Amount Paid	Paid/Day	Units/Day	Claims/Member	% Cost
Gemfibrozil	GEMFIBROZIL TAB 600MG	4,896	1,210	\$83,255.54	\$0.53	1.93	4.05	7.49%
Fenofibrate	TRICOR TAB 145MG	2,796	708	\$554,758.22	\$4.74	1.01	3.95	49.91%
Choline Fenofibrate	TRILIPIX CAP 135MG	1,713	432	\$323,229.95	\$4.47	1.01	3.97	29.08%
Fenofibrate	FENOFIBRATE TAB 160MG	742	256	\$53,090.12	\$1.67	1.01	2.9	4.78%
Fenofibrate	TRICOR TAB 48MG	457	122	\$30,178.16	\$1.73	1.09	3.75	2.72%
Fenofibrate Micronized	FENOFIBRATE CAP 134MG	385	99	\$20,355.26	\$1.36	1	3.89	1.83%
Choline Fenofibrate	TRILIPIX CAP 45MG	225	59	\$12,487.08	\$1.52	1.02	3.81	1.12%
Fenofibrate Micronized	FENOFIBRATE CAP 200MG	195	39	\$15,277.93	\$1.99	1	5	1.37%
Fenofibrate	FENOFIBRATE TAB 54MG	186	66	\$4,398.04	\$0.72	1	2.82	0.40%
Fenofibrate	TRIGLIDE TAB 160MG	137	30	\$4,588.27	\$0.97	1	4.57	0.41%
Fenofibrate Micronized	FENOFIBRATE CAP 67MG	52	13	\$1,643.55	\$0.90	1.1	4	0.15%
Fenofibrate Micronized	ANTARA CAP 130MG	26	5	\$4,878.13	\$5.08	1	5.2	0.44%
Fenofibrate	TRIGLIDE TAB 50MG	12	6	\$915.57	\$2.54	1.25	2	0.08%
Fenofibrate	LIPOFEN CAP 150MG	4	1	\$1,261.88	\$3.51	1	4	0.11%
Fenofibrate	FENOGLIDE TAB 120MG	4	3	\$1,147.39	\$4.78	1	1.33	0.10%
Total		11,830	2,861*	\$1,111,465.09	\$2.51	1.34	4.13	100.00%

*Unduplicated total number of members.